Is tremelimumab included in medical insurance?

Tremelimumab (tremelimumab) is a cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) blocking antibody developed by AstraZeneca under a license from Pfizer for the treatment of a range of malignancies. Tesstumumab was approved in the United States in October 2022 in combination with durvalumab for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). Subsequently, temsitumumab combined with durvalumab and platinum-based The basic chemotherapy regimen is approved in the United States for the treatment of adult patients with metastatic non-small cell lung cancer (mNSCLC) who do not have sensitizing epidermal growth factor receptor mutations or anaplastic lymphoma kinase genomic tumor abnormalities.

Texitumumab can block the activity of CTLA-4, which helps activate T cells, triggers an immune response to cancer, and promotes cancer cell death. Outside of the HIMALAYA study, temsilimumab is being tested in combination with imrvalumab in multiple tumor types, including localized HCC, SCLC and bladder cancer. According to the results of the trial, the combination of the two drugs improved overall survival and progression-free survival compared with chemotherapy alone.

Tesetumumab is an emerging cancer immunotherapy drug. It is a prescription drug and has not yet been launched in China. Therefore, it has not been included in the medical insurance list. Domestic patients cannot yet purchase this drug. The U.S. version of temsitumumab the original drug has been on the market overseas for a short time and is sold under the trade name Imjudo. The price is not yet clear, and there are currently no generic versions of temsitumumab produced and launched. For specific prices and drug details, please consult a medical consultant.